StockMirror — Stock Screener

LINCOLN Q3 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Lincoln Pharma reported strong Q3 FY26 results with revenue up 13.5% YoY and PAT up 37.7% YoY, driven by operational performance and significant other income. The company is progressing on its long-term INR 1,000 crore target via organic initiatives (Cepha block, new R&D center, regulated market entry) and is actively seeking inorganic opportunities. Margin guidance is cautious (15-18% EBITDA), with profitability bolstered by forex/investment gains. Key focuses are balanced growth and margins, with exports being the major revenue contributor.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Targeting 12-18% revenue growth while guiding for EBITDA margins between 15-18%. Investing in growth (R&D, expansions) while maintaining profitability.

About Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited (LINCOLN) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More